Anthos Therapeutics News and Resources

Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on cardiometabolic diseases, has reached an agreement to be acquired by Novartis for up to $3.1 billion. The acquisition, announced today, includes an initial payment of $925 million upon closing, with additional